|
|
1.
|
A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): Rationale and design. MedStar authors:
Year: 2016
Citation: - American Heart Journal. 177:66-73, 2016 Jul
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Alvaro G, Amantea B, Auci E, Auriemma S, Baiocchi M, Bianchi A, Biondi-Zoccai G, Bove T, Bradic N, Buscaglia G, Calabro MG, Cariello C, Corcione A, De Vuono G, Fominskiy E, Frontini M, Galdieri N, Gemma M, Gianni S, Grigoryev E, Guarracino F, Landoni G, Lembo R, Likhvantsev V, Lipinski MJ, Lobreglio R, Lomivorotov VV, Monaco F, Pala G, Paternoster G, Pisano A, Sangalli F, Wang CY, Zangrillo A, Zucchetti MC
|
|
|
2.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(8):724-34, 2015 Feb 19.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
